{"id":"https://openalex.org/W2229855073","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.8030","title":"Pharmacogenomic analysis from a phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC)","display_name":"Pharmacogenomic analysis from a phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC)","publication_year":2009,"publication_date":"2009-05-20","ids":{"openalex":"https://openalex.org/W2229855073","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.8030","mag":"2229855073"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.15_suppl.8030","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.8030","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.8030","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016904876","display_name":"Egbert Frederik Smit","orcid":"https://orcid.org/0000-0002-7329-6995","observed_orcids":["https://orcid.org/0000-0002-7329-6995"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"E. F. Smit","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"M. A. Socinski","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111959681","display_name":"Brian P. Mullaney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"B. P. Mullaney","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083307676","display_name":"Scott P. Myrand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"S. P. Myrand","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049919051","display_name":"Emily Powell","orcid":"https://orcid.org/0000-0001-7430-3176","observed_orcids":["https://orcid.org/0000-0001-7430-3176"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"E. Powell","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069095893","display_name":"Paul C. Lorigan","orcid":"https://orcid.org/0000-0002-8875-2164","observed_orcids":["https://orcid.org/0000-0002-8875-2164"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"P. Lorigan","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":null,"display_name":"C. Kaiser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"C. Kaiser","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112252143","display_name":"Susan C. Guba","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"S. C. Guba","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110052001","display_name":"N. Thatcher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"N. Thatcher","raw_affiliation_strings":["VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"VU University Medical Center, Amsterdam, Netherlands; University of North Carolina, Chapel Hill, NC; Eli Lilly and Company, Indianapolis, IN; The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4210133995"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"15_suppl","first_page":"8030","last_page":"8030"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.8529999852180481,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.8529999852180481,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.09740000218153,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.03229999914765358,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/extensive-stage-small-cell-lung-cancer","display_name":"extensive-stage small cell lung cancer","score":0.8539999723434448},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.8069999814033508},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9589999914169312},{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.996999979019165},{"id":"https://openalex.org/keywords/pharmacogenomics","display_name":"pharmacogenomics","score":0.7160000205039978},{"id":"https://openalex.org/keywords/thymidylate-synthase","display_name":"thymidylate synthase","score":0.9679999947547913},{"id":"https://openalex.org/keywords/ercc1","display_name":"ERCC1","score":0.9700000286102295},{"id":"https://openalex.org/keywords/folylpolyglutamate-synthetase","display_name":"folylpolyglutamate synthetase","score":0.8840000033378601},{"id":"https://openalex.org/keywords/slc19a1","display_name":"SLC19A1","score":0.8769999742507935},{"id":"https://openalex.org/keywords/folylpolyglutamate-synthase","display_name":"FPGS","score":0.7269999980926514},{"id":"https://openalex.org/keywords/mthfr","display_name":"MTHFR","score":0.7580000162124634},{"id":"https://openalex.org/keywords/folate-pathway","display_name":"folate pathway","score":0.4339999854564667},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6320000290870667},{"id":"https://openalex.org/keywords/chemotherapy-naive-patients","display_name":"chemotherapy-naive patients","score":0.7070000171661377},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.6700000166893005},{"id":"https://openalex.org/keywords/single-nucleotide-polymorphisms","display_name":"single nucleotide polymorphisms","score":0.753000020980835},{"id":"https://openalex.org/keywords/immunohistochemistry","display_name":"immunohistochemistry","score":0.8100000023841858},{"id":"https://openalex.org/keywords/platinum-chemotherapy-response","display_name":"platinum chemotherapy response","score":0.367000013589859}],"concepts":[{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.8306412100791931},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.7608073949813843},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5843596458435059},{"id":"https://openalex.org/C2779309665","wikidata":"https://www.wikidata.org/wiki/Q17917256","display_name":"ERCC1","level":5,"score":0.5616339445114136},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5342134237289429},{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.46326735615730286},{"id":"https://openalex.org/C123321153","wikidata":"https://www.wikidata.org/wiki/Q22676802","display_name":"Thymidylate synthase","level":4,"score":0.45014646649360657},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4245266318321228},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4141961634159088},{"id":"https://openalex.org/C153209595","wikidata":"https://www.wikidata.org/wiki/Q501128","display_name":"Single-nucleotide polymorphism","level":4,"score":0.4101908802986145},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2979004383087158},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2875770926475525},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.21418681740760803},{"id":"https://openalex.org/C2780456651","wikidata":"https://www.wikidata.org/wiki/Q238512","display_name":"Fluorouracil","level":3,"score":0.12303006649017334},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.06846487522125244},{"id":"https://openalex.org/C135763542","wikidata":"https://www.wikidata.org/wiki/Q106016","display_name":"Genotype","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.0},{"id":"https://openalex.org/C104451858","wikidata":"https://www.wikidata.org/wiki/Q2714458","display_name":"Nucleotide excision repair","level":4,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2009.27.15_suppl.8030","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.8030","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.8030","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/26badf4a-eb03-4544-8346-6bc379a161e5","doi":null,"is_oa":false,"landing_page_url":"http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000276606605232&KeyUID=WOS:000276606605232","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Smit, E F, Socinski, M A, Mullaney, B P, Myrand, S P, Powell, E, Lorigan, P, Kaiser, C, Guba, S C & Thatcher, N 2009, 'Pharmacogenomic analysis from a phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC)', Journal of Clinical Oncology, vol. 27, no. 15, 8030.","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2146583854","https://openalex.org/W2602223431","https://openalex.org/W2242689996","https://openalex.org/W2085315176","https://openalex.org/W2999999222","https://openalex.org/W4320932557","https://openalex.org/W2065437218","https://openalex.org/W7095169492","https://openalex.org/W2051945890","https://openalex.org/W2537220217"],"abstract_inverted_index":{"8030":[0],"Background:":[1],"We":[2],"have":[3],"reported":[4],"results":[5,37,312],"of":[6,38,51,278,309],"a":[7],"randomized":[8],"phase":[9],"III":[10],"trial":[11],"in":[12,55,166,243,289,296],"chemonaive":[13],"patients":[14,176],"with":[15,177,223,253,287,304],"ED-SCLC":[16],"comparing":[17],"PC":[18,173,200],"to":[19,171,230],"EC.":[20],"Study":[21],"enrollment":[22],"was":[23,193,220,232,250],"closed":[24],"for":[25,108,136,149,155,175,202,234,255],"futility":[26],"but":[27],"pharmacogenomic":[28,311],"endpoints":[29],"were":[30,70,93,106,134,153,302],"not":[31,213,221],"reported.":[32],"Here":[33],"we":[34],"report":[35],"the":[36,167,172,199,290],"immunohistochemistry":[39],"(IHC)":[40],"analysis":[41,50,308],"from":[42,90,99],"tumor":[43,279],"tissues":[44],"and":[45,84,126,131,269,272,300],"single":[46],"nucleotide":[47],"polymorphism":[48],"(SNP)":[49],"selected":[52],"genes":[53],"implicated":[54],"pemetrexed,":[56],"carboplatin,":[57],"or":[58],"etoposide":[59],"activity.":[60],"Methods:":[61],"Proteins":[62],"studied":[63],"by":[64,95,225],"validated":[65],"IHC":[66,161],"on":[67],"Benchmark":[68],"XT":[69],"thymidylate":[71],"synthase":[72],"(TS),":[73],"excision":[74],"repair":[75],"cross":[76],"complementing-1":[77],"(ERCC1),":[78],"glycinamide":[79],"ribonucleotide":[80],"formyl":[81],"transferase":[82],"(GARFT),":[83],"folylpolyglutamate":[85],"synthetase":[86],"(FPGS).":[87],"SNP":[88,227,247],"data":[89],"whole":[91],"blood":[92],"genotyped":[94,107],"massArray":[96],"mass":[97],"spectrometry":[98],"611":[100],"samples.":[101],"One":[102],"hundred":[103],"fifty-eight":[104],"SNPs":[105,268,295],"TS,":[109],"FPGS,":[110],"\u03b3-glutamyl":[111],"hydrolase":[112],"(GGH),":[113],"methylene":[114],"tetrahydrofolate":[115],"reductase":[116],"(MTHFR),":[117],"folate":[118],"receptor-":[119],"\u03b1":[120],"(FR-\u03b1),":[121],"solute":[122],"carrier":[123],"19A1":[124],"(SLC19A1)":[125],"adjacent":[127],"regions.":[128],"Allele":[129],"frequency":[130],"Hardy-Weinberg":[132],"equilibrium":[133],"calculated":[135],"each":[137],"SNP.":[138],"Results:":[139],"Of":[140],"408":[141],"tissue":[142],"samples":[143,152,280],"(from":[144],"908":[145],"enrolled":[146],"pts)":[147],"available":[148],"IHC,":[150],"336":[151],"assayed":[154],">":[156],"1":[157],"assay":[158],"target.":[159],"The":[160],"analyses":[162,263,277],"showed":[163],"improved":[164,235],"OS":[165,236,256,288],"EC":[168,291],"arm":[169,174,201],"relative":[170],"low":[178,203,209,283],"TSnuclear":[179,284],"(12.9":[180],"vs":[181,208],"7.5":[182],"month,":[183],"p":[184,188,240,258],"<":[185],"0.001,":[186],"interaction":[187],"value":[189,259],"=":[190,238,241,260],"0.017).":[191],"There":[192],"no":[194],"differential":[195],"treatment":[196,254],"effect":[197],"within":[198,271],"vs.":[204],"high":[205],"TS.":[206],"High":[207],"ERCC1":[210],"levels":[211],"did":[212],"predict":[214],"outcome":[215,224],"following":[216],"C":[217],"exposure.":[218],"GARFT":[219],"associated":[222,252,303],"treatment.":[226],"rs2838952":[228],"(adjacent":[229],"SLC19A1)":[231],"significant":[233],"(HR":[237],"0.590,":[239],"0.01)":[242],"both":[244],"study":[245],"arms.":[246],"rs12379987":[248],"(FPGS)":[249],"significantly":[251],"(interaction":[257],"0.036).":[261],"Exploratory":[262],"found":[264],"associations":[265],"between":[266],"additional":[267],"PFS":[270],"across":[273],"treatments.":[274],"Conclusions:":[275],"Pharmacogenomic":[276],"show":[281],"that":[282],"expression":[285],"correlates":[286],"arm.":[292],"Two":[293],"germline":[294],"regions":[297],"including":[298],"FPGS":[299],"SLC19A1":[301],"better":[305],"OS.":[306],"Further":[307],"these":[310],"is":[313],"ongoing.":[314],"[Table:":[315],"see":[316],"text]":[317]},"counts_by_year":[],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2016-06-24T00:00:00"}